scholarly article | Q13442814 |
P50 | author | Dick Lindhout | Q30500447 |
Sergiusz Jóźwiak | Q55719494 | ||
Rosemary Ekong | Q91679560 | ||
P2093 | author name string | M Nellist | |
J P Cheadle | |||
J R Sampson | |||
D J Kwiatkowski | |||
J Nahmias | |||
J R Yates | |||
M Fox | |||
J Wolfe | |||
J Young | |||
A C Jones | |||
M Tachataki | |||
R G Snell | |||
E P Henske | |||
J Kwiatkowska | |||
J Osborne | |||
M P Short | |||
S Povey | |||
P Richardson | |||
C Munro | |||
S Verhoef | |||
S Ward | |||
A J Green | |||
S Jeremiah | |||
B Janssen | |||
C Hermans | |||
T L Hawkins | |||
A van den Ouweland | |||
T Sepp | |||
D Halley | |||
K Woodward | |||
M van Slegtenhorst | |||
M P Reeve | |||
D Ravine | |||
J H Haines | |||
J B Ali | |||
F Wilmer | |||
M Burley | |||
R de Hoogt | |||
P433 | issue | 5327 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | tuberous sclerosis | Q1362721 |
P304 | page(s) | 805-8 | |
P577 | publication date | 1997-08-08 | |
P1433 | published in | Science | Q192864 |
P1476 | title | Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 | |
P478 | volume | 277 |
Q21093295 | 13-year-old tuberous sclerosis patient with renal cell carcinoma associated with multiple renal angiomyolipomas developing multifocal micronodular pneumocyte hyperplasia |
Q54740041 | A 34 bp deletion within TSC2 is a rare polymorphism, not a pathogenic mutation. |
Q34129641 | A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis |
Q28079929 | A Subset of Autism-Associated Genes Regulate the Structural Stability of Neurons. |
Q35836708 | A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism |
Q30597707 | A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits |
Q34894950 | A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex |
Q28588779 | A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice |
Q73779009 | A new twist for the tumour suppressor hamartin |
Q55003754 | A novel TSC2 missense variant associated with a variable phenotype of tuberous sclerosis complex: case report of a Chinese family. |
Q53065574 | A novel TSC2 mutation in a Chinese family with tuberous sclerosis complex |
Q35838450 | A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis |
Q42354555 | A reliable cell-based assay for testing unclassified TSC2 gene variants |
Q84408540 | A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity |
Q32046901 | A whole-genome analysis of allelic changes in renal cell carcinoma by in-gel competitive reassociation |
Q35962474 | Aberrant cellular differentiation and migration in renal and pulmonary tuberous sclerosis complex. |
Q36094125 | Aberrant differentiation of Tsc2-deficient teratomas associated with activation of the mTORC1-TFE3 pathway |
Q34008821 | Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1 |
Q33559748 | Abnormal Neural Progenitor Cells Differentiated from Induced Pluripotent Stem Cells Partially Mimicked Development of TSC2 Neurological Abnormalities |
Q34575565 | Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex |
Q30912254 | Abnormal sudomotor function in the hypomelanotic macules of tuberous sclerosis complex |
Q40187301 | Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex |
Q24320102 | Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning |
Q37370345 | Adult reversal of cognitive phenotypes in neurodevelopmental disorders |
Q41721405 | Advances in fluorescent in situ hybridisation |
Q33975495 | Advances in the understanding of tuberous sclerosis. |
Q29620397 | Akt regulates growth by directly phosphorylating Tsc2 |
Q42798601 | Akt regulates nuclear/cytoplasmic localization of tuberin |
Q36957948 | Alterations of phosphatidylinositol 3-kinase pathway components in epilepsy-associated glioneuronal lesions |
Q35907033 | Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia |
Q26798087 | Amino acid management in cancer |
Q27009377 | Amino acids and mTORC1: from lysosomes to disease |
Q37279405 | Amplicon Resequencing Identified Parental Mosaicism for Approximately 10% of "de novo" SCN1A Mutations in Children with Dravet Syndrome |
Q34044641 | Amplification of 9q34 in childhood adrenocortical tumors: a specific feature unrelated to ethnic origin or living conditions |
Q43552546 | An Australian tuberous sclerosis cohort: are surveillance guidelines being met? |
Q39097827 | An Overview of Autosomal Dominant Tumour Syndromes with Prominent Features in the Oral and Maxillofacial Region. |
Q38255292 | An approach to cystic kidney diseases: the clinician's view |
Q38001798 | An overview of the mTOR pathway as a target in cancer therapy. |
Q35434502 | An unbalanced submicroscopic translocation t(8;16)(q24.3;p13.3)pat associated with tuberous sclerosis complex, adult polycystic kidney disease, and hypomelanosis of Ito. |
Q34444616 | Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations |
Q47353674 | Analysis of TSC1 mutation spectrum in mucosal melanoma |
Q42667240 | Analysis of TSC2 stop codon variants found in tuberous sclerosis patients |
Q28146039 | Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis |
Q50580930 | Analysis of genotypes and phenotypes in Chinese children with tuberous sclerosis complex |
Q36643591 | Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. |
Q52324861 | Antenatal screening and diagnosis of tuberous sclerosis complex by fetal echocardiography and targeted genomic sequencing |
Q41743274 | Applied molecular genetic techniques for prenatal diagnosis |
Q26740254 | Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture |
Q36459311 | Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial |
Q51733792 | Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial |
Q41514066 | Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/- Mice |
Q37202922 | Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients |
Q36780387 | Association of AMP-Activated Protein Kinase with Risk and Progression of Non–Hodgkin Lymphoma |
Q48495929 | Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures |
Q56032207 | Autism and tuberous sclerosis |
Q50313466 | Autism in tuberous sclerosis: evoked potential evidence for a deficit in auditory sensory processing |
Q37068738 | Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses |
Q55339450 | Autism spectrum disorder: prospects for treatment using gene therapy. |
Q36101188 | Autism spectrum disorders: from genes to neurobiology |
Q89841014 | Autophagy in Rare (NonLysosomal) Neurodegenerative Diseases |
Q27000191 | Autophagy in malignant transformation and cancer progression |
Q36384361 | Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells |
Q50309438 | Behavior problems in children with tuberous sclerosis complex and parental stress |
Q33899858 | Biallelic TSC gene inactivation in tuberous sclerosis complex |
Q77132898 | Biallelic mutations of theTsc2 gene in chemically induced rat renal cell carcinoma |
Q81212410 | Bilateral massive renal angiomyolipoma concurrent with oncocytoma in tuberous sclerosis complex associated with pulmonary lymphangioleiomyomatosis |
Q37077179 | Bilateral renal cell carcinoma in a paediatric patient with tuberous sclerosis complex |
Q43717822 | Biological behavior and tumorigenesis of subependymal giant cell astrocytomas |
Q48254639 | Biological markers of intellectual disability in tuberous sclerosis |
Q80510573 | Biology and therapy of malignant solid tumors in childhood |
Q37077832 | Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. |
Q41776053 | Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice |
Q43154847 | Bipolar disorder and tuberous sclerosis complex: is it a mere coincidence? |
Q39137809 | Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms |
Q36746057 | Blocking rpS6 Phosphorylation Exacerbates Tsc1 Deletion-Induced Kidney Growth |
Q97520827 | Brain Proteomic Profiling in Intractable Epilepsy Caused by TSC1 Truncating Mutations: A Small Sample Study |
Q30977127 | Brain abnormalities in tuberous sclerosis complex |
Q34718140 | Brain overgrowth in disorders of RTK-PI3K-AKT signaling: a mosaic of malformations |
Q32054896 | CT and MR imaging of cerebral tuberous sclerosis |
Q34322773 | Cancer-associated genodermatoses and familial cancer syndromes with cutaneous manifestations |
Q53086918 | Cardiac masses and tumours |
Q36788885 | Cardiac myocyte cell cycle control in development, disease, and regeneration |
Q35115152 | Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group |
Q54390911 | Case Report A novel TSC1 mutation (c.1964delA) in a Chinese patient with tuberous sclerosis complex |
Q57786833 | Cathepsin-k expression in pulmonary lymphangioleiomyomatosis |
Q40432968 | Causes of mortality in individuals with tuberous sclerosis complex. |
Q28208783 | Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B |
Q28191528 | Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38 |
Q37240068 | Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers |
Q26864843 | Cellular and synaptic network defects in autism |
Q48183980 | Cellular senescence of angiofibroma stroma cells from patients with tuberous sclerosis |
Q46114126 | Central nervous system malformations: gene locations of known human mutations |
Q33793036 | Central nervous system malformations: locations of known human mutations |
Q30989503 | Cerebellar Development and Autism Spectrum Disorder in Tuberous Sclerosis Complex |
Q42578506 | Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients |
Q22010879 | Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin |
Q48785674 | Characterizing magnetoencephalographic spike sources in children with tuberous sclerosis complex |
Q47759558 | Childhood-Onset Epileptic Encephalopathy Associated With Isolated Focal Cortical Dysplasia and a Novel TSC1 Germline Mutation |
Q55981825 | Chromosome 16 Loss of Heterozygosity in Tuberous Sclerosis and Sporadic Lymphangiomyomatosis |
Q37871915 | Clinical activity of mammalian target of rapamycin inhibitors in solid tumors |
Q37901793 | Clinical genomics of renal epithelial tumors |
Q47826008 | Clinical management of tuberous sclerosis complex over the lifetime of a patient. |
Q48088816 | Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma |
Q35224736 | Clinically relevant imaging in tuberous sclerosis |
Q46646341 | Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex |
Q40083141 | Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment |
Q50306912 | Cognitive and behavioral correlates of tuberous sclerosis complex |
Q37726384 | Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex |
Q48698351 | Comparative analysis of MR sequences to detect structural brain lesions in tuberous sclerosis |
Q39142069 | Comparative analysis ofTsc1andTsc2single and double radial glial cell mutants |
Q91679568 | Comparison of the functional and structural characteristics of rare TSC2 variants with clinical and genetic findings |
Q33711691 | Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors |
Q42698835 | Complete inactivation of the TSC2 gene leads to formation of hamartomas |
Q38040446 | Complex single gene disorders and epilepsy. |
Q24540242 | Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. |
Q37465002 | Computational Systems Bioinformatics and Bioimaging for Pathway Analysis and Drug Screening |
Q43201184 | Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast |
Q34488131 | Control of growth and organ size in Drosophila |
Q34099221 | Cortical malformations and epilepsy |
Q40583829 | Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex |
Q27685230 | Crystal structure of the yeast TSC1 core domain and implications for tuberous sclerosis pathological mutations |
Q34816124 | Current management of tuberous sclerosis complex |
Q47370738 | Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function |
Q39239920 | DEPDC5 as a potential therapeutic target for epilepsy |
Q35801388 | Deconvoluting mTOR biology |
Q48871907 | Decreased benzodiazepine receptor and increased GABA level in cortical tubers in tuberous sclerosis complex |
Q43947306 | Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma |
Q73443286 | Denaturing high-performance liquid chromatography (DHPLC) is a highly sensitive, semi-automated method for identifying mutations in the TSC1 gene |
Q43565706 | Denaturing high-performance liquid chromatography (DHPLC)-based prenatal diagnosis for tuberous sclerosis |
Q26995242 | Dendritic spine dysgenesis in autism related disorders |
Q34474235 | Deregulation of genetic pathways in neuroendocrine tumors |
Q35108646 | Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence |
Q34996620 | Diabetic flies? Using Drosophila melanogaster to understand the causes of monogenic and genetically complex diseases. |
Q51979366 | Diagnosing genetic anomalies by inspection. |
Q48316330 | Diagnosis and management of tuberous sclerosis complex |
Q34552831 | Diagnosis of tuberous sclerosis complex |
Q39069971 | Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment |
Q28360959 | Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex |
Q48283933 | Diffusion tensor imaging of commissural and projection white matter in tuberous sclerosis complex and correlation with tuber load |
Q28087577 | Discovery of Rare Mutations in Autism: Elucidating Neurodevelopmental Mechanisms |
Q38134658 | Diseases of the tooth: the genetic and molecular basis of inherited anomalies affecting the dentition |
Q45106443 | Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex |
Q37397454 | Distinctive responses to nitrogen starvation in the dominant active mutants of the fission yeast Rheb GTPase |
Q73002003 | Distribution of Tsc1 protein detected by immunohistochemistry in various normal rat tissues and the renal carcinomas of Eker rat: detection of limited colocalization with Tsc1 and Tsc2 gene products in vivo |
Q51974501 | Downregulation of glutamate receptor subunit 2(3) in subependymal giant-cell tumor |
Q47211341 | Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size |
Q37729341 | Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder? |
Q34380413 | Dysregulation of the TSC-mTOR pathway in human disease |
Q34368117 | EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. Second of two parts. |
Q92519620 | Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study |
Q48479367 | Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis |
Q90704464 | Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization |
Q48096412 | Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density |
Q73491877 | Effects of pregnancy on the renal and pulmonary manifestations in women with tuberous sclerosis complex |
Q45158558 | Effects of rapamycin in the Eker rat model of tuberous sclerosis complex |
Q57178617 | Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial |
Q31140724 | Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study |
Q64239165 | Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis |
Q24619170 | Emerging Pharmacotherapies for Neurodevelopmental Disorders |
Q34240649 | Emerging Treatments in the Management of Tuberous Sclerosis Complex |
Q30475253 | Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes |
Q33712434 | Endocytosis and mitogenic signaling |
Q34755802 | Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex |
Q89428615 | Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum |
Q34386806 | Epilepsy and genetic malformations of the cerebral cortex |
Q26829946 | Epilepsy related to developmental tumors and malformations of cortical development |
Q33790613 | Erzhi Pill® Repairs Experimental Liver Injury via TSC/mTOR Signaling Pathway Inhibiting Excessive Apoptosis. |
Q44173030 | Evaluation of carcinogenic responses in the Eker rat following short-term exposure to selected nephrotoxins and carcinogens |
Q47589182 | Evaluation of mTOR signaling pathway proteins in rat gastric mucosa exposed to sulfite and ghrelin. |
Q38066584 | Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
Q48701608 | Everolimus alters white matter diffusion in tuberous sclerosis complex |
Q38408393 | Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. |
Q36929881 | Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation |
Q37909448 | Everolimus tablets for patients with subependymal giant cell astrocytoma |
Q34385154 | Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations: Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and Lymph Nodes from Women with Lymphangiomyomatosis |
Q33827600 | Evidence for population variation in TSC1 and TSC2 gene expression |
Q40749976 | Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation |
Q33698618 | Evidence that TSC2 acts as a transcription factor and binds to and represses the promoter of Epiregulin |
Q38079547 | Evolving neurobiology of tuberous sclerosis complex |
Q37025863 | Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas |
Q79195309 | Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex |
Q50305423 | Expression of microRNAs miR21, miR146a, and miR155 in tuberous sclerosis complex cortical tubers and their regulation in human astrocytes and SEGA-derived cell cultures |
Q48003070 | Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology |
Q55068899 | Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. |
Q33681400 | Familial cylindromatosis mimicking tuberous sclerosis complex and confirmation of the cylindromatosis locus, CYLD1, in a large family |
Q47552062 | Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report |
Q64114838 | Familial multifocal micronodular pneumocyte hyperplasia with a novel splicing mutation in TSC1: Three cases in one family |
Q34480137 | Familial neurogenic tumor syndromes |
Q24310626 | Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver |
Q36457269 | Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation |
Q35099876 | Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy? |
Q34525200 | Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. |
Q77931512 | Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31 |
Q48446962 | Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas |
Q38012951 | From genes to cognition in tuberous sclerosis: Implications for mTOR inhibitor-based treatment approaches |
Q33750454 | From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis |
Q35014198 | Frontier of Epilepsy Research - mTOR signaling pathway |
Q82915005 | Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex |
Q47246862 | Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex |
Q44846704 | Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex |
Q33321312 | Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex |
Q39589774 | Functional characterization of the TSC2 c.3598C>T (p.R1200W) missense mutation that co‐segregates with tuberous sclerosis complex in mildly affected kindreds |
Q35789048 | Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis |
Q26750737 | GEP- NETS UPDATE: Genetics of neuroendocrine tumors |
Q35105998 | Gastrointestinal Inherited Polyposis Syndromes |
Q28115142 | GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR |
Q34663430 | Gene expression analysis as a strategy to understand the molecular pathogenesis of infantile spasms |
Q33926192 | Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors |
Q33243918 | Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes |
Q36630119 | Gene profiling in temporal lobe epilepsy tissue and dysplastic lesions |
Q48299820 | Generation of a conditional disruption of the Tsc2 gene |
Q24626239 | Genetic Interstitial Lung Disease |
Q55463829 | Genetic diseases and glioblastomas |
Q34783505 | Genetic insights into familial cancers-- update and recent discoveries |
Q28243987 | Genetic malformations of the cerebral cortex and epilepsy |
Q33685187 | Genetic malformations of the human cerebral cortex |
Q39023793 | Genetic predisposition to kidney cancer |
Q46075544 | Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies |
Q36373332 | Genetic testing in diffuse parenchymal lung disease |
Q91048652 | Genetically engineered human cortical spheroid models of tuberous sclerosis |
Q64283563 | Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms |
Q37214956 | Genetics and molecular biology of tuberous sclerosis complex |
Q35236356 | Genetics of inherited human epilepsies |
Q37536133 | Genetics of tuberous sclerosis complex: implications for clinical practice |
Q34031558 | Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins |
Q47149979 | Genotype and brain pathology phenotype in children with tuberous sclerosis complex |
Q35899354 | Genotype and cognitive phenotype of patients with tuberous sclerosis complex |
Q51994229 | Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States |
Q34384437 | Germ-Line Mutational Analysis of the TSC2 Gene in 90 Tuberous-Sclerosis Patients |
Q34389302 | Germ-line mosaicism in tuberous sclerosis: how common? |
Q57494856 | Giant Perivascular Epithelioid Cell Tumor of the Orbit: A Clinicopathological Analysis and Review of the Literature |
Q28256696 | Giant cells: contradiction to two-hit model of tuber formation? |
Q81142605 | Giant cells: contradiction to two-hit model of tuber formation? |
Q53517722 | Glioblastoma multiforme in a child with tuberous sclerosis complex |
Q43552410 | Hamartin and tuberin expression in human tissues |
Q28205432 | Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B |
Q31913107 | Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures |
Q36564078 | Hepatic angiomyolipoma: differential diagnosis from other liver tumors in a special reference to vascular imaging - importance of early drainage vein |
Q37976482 | Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis |
Q39244240 | Hereditary Kidney Cancer Syndromes and Surgical Management of the Small Renal Mass |
Q55083786 | Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management. |
Q37412363 | Hereditary kidney cancer syndromes |
Q36904561 | Hereditary neuroendocrine tumors of the gastroenteropancreatic system |
Q48592496 | Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. |
Q49650210 | Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming |
Q34389755 | High rate of mosaicism in tuberous sclerosis complex |
Q36645990 | High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma |
Q83925818 | High-Resolution Melting Analysis Is a More Effective Approach for ScreeningTSCGenes Mutations |
Q64115751 | Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex |
Q34663467 | Histopathology of brain tissue from patients with infantile spasms |
Q36716842 | Hitting the mark in hamartoma syndromes. |
Q37461807 | Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation |
Q84936981 | Horseshoe kidney and a rare TSC2 variant in two unrelated individuals with tuberous sclerosis complex |
Q33850885 | How to construct a neural tube |
Q28264728 | Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin |
Q36505662 | Hypoxia-inducible factor-1a contributes to dendritic overgrowth in tuberous sclerosis |
Q24304395 | Identification and characterization of the interaction between tuberin and 14-3-3zeta |
Q58033502 | Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations |
Q24322703 | Identification of TBC7 having TBC domain as a novel binding protein to TSC1-TSC2 complex |
Q89901888 | Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology |
Q40620346 | Identification of a core promoter and a novel isoform of the human TSC1 gene transcript and structural comparison with mouse homolog. |
Q33502350 | Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex |
Q35143110 | Identification of regions critical for the integrity of the TSC1-TSC2-TBC1D7 complex |
Q33845794 | Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. |
Q28292197 | Identification of the epileptogenic tuber in patients with tuberous sclerosis: a comparison of high-resolution EEG and MEG |
Q33773155 | Imaging of single DNA molecule: applications to high-resolution genomic studies |
Q36410001 | Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis |
Q42645301 | In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor |
Q33604295 | Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2 |
Q59298210 | Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study |
Q51529165 | Increased expression of tuberin in human uterine leiomyoma |
Q37872029 | Inflammation in epilepsy: clinical observations |
Q35851661 | Inherited forms of renal cell carcinoma |
Q35476371 | Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice |
Q42807105 | Initial presentation with dilated cardiomyopathy in a patient of tuberous sclerosis: A rare case report |
Q34417182 | Insulin Signaling: Lessons from the Drosophila Tuberous Sclerosis Complex, a Tumor Suppressor |
Q30983931 | Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation |
Q40498907 | Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins |
Q50109448 | Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex |
Q96023037 | Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma |
Q39268078 | Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network |
Q55475713 | Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. |
Q34056666 | Ionizing radiation and genetic risks. XII. The concept of "potential recoverability correction factor" (PRCF) and its use for predicting the risk of radiation-inducible genetic disease in human live births |
Q35085208 | Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor |
Q34157385 | Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. |
Q28071388 | Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives |
Q40467620 | Knockout of a Tuberous Sclerosis Gene Highlights Role of Glia in Epileptogenesis |
Q33301152 | Laser skin resurfacing and fibrin sealing as successful treatment for facial angiofibromas in tuberous sclerosis |
Q38992291 | Lessons learned from studying syndromic autism spectrum disorders |
Q97555573 | Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders |
Q48508465 | Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial |
Q36100341 | Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway |
Q24538838 | Linkage of the Gene for an Autosomal Dominant Form of Juvenile Amyotrophic Lateral Sclerosis to Chromosome 9q34 |
Q34651253 | Lipid posttranslational modifications. Farnesyl transferase inhibitors |
Q35788341 | Loss of Heterozygosity on Chromosomes 9q and 16p in Atypical Adenomatous Hyperplasia Concomitant with Adenocarcinoma of the Lung |
Q37128350 | Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse |
Q41485973 | Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma |
Q44365146 | Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas |
Q33603083 | Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development |
Q77072086 | Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia |
Q43043692 | Loss of heterozygosity on tuberous sclerosis complex genes in multifocal micronodular pneumocyte hyperplasia |
Q34987845 | Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration |
Q35764929 | Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors |
Q28568651 | Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis |
Q28507521 | Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation |
Q57793715 | Lost in Translation: Traversing the Complex Path from Genomics to Therapeutics in Autism Spectrum Disorder |
Q34536450 | Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies |
Q36357766 | Lymphangioleiomyomatosis - a wolf in sheep's clothing. |
Q42595723 | Lymphangioleiomyomatosis: A Monogenic Model of Malignancy |
Q38484497 | Lymphangioleiomyomatosis: New Treatment Perspectives |
Q36067383 | Lymphangioleiomyomatosis: what do we know and what are we looking for? |
Q34560457 | Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis |
Q100750562 | MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61 |
Q41672627 | MR imaging of tuberous sclerosis in neonates and young infants. |
Q56232687 | Malformations of cortical development and epilepsy |
Q33993991 | Malignant mesenteric perivascular epithelioid cell neoplasm presenting as an intra-abdominal fistula in a 49-year-old female. |
Q36193682 | Malignant perivascular epithelioid cell neoplasm of the mediastinum and the lung: one case report |
Q37432305 | Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases |
Q43814142 | Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex |
Q46697537 | Management of epilepsy in tuberous sclerosis complex. |
Q37758485 | Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. |
Q35962461 | Managing epilepsy in tuberous sclerosis complex |
Q39048621 | Manifestations of Tuberous Sclerosis Complex: The Experience of a Provincial Clinic |
Q30746587 | Mechanism-based treatment in tuberous sclerosis complex |
Q36922578 | Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation |
Q64075806 | Mechanistic Target of Rapamycin Pathway in Epileptic Disorders |
Q35777641 | Merlin and the ERM proteins in Schwann cells, neurons and growth cones |
Q41365464 | Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation. |
Q28472728 | Metabolic regulation of neuronal plasticity by the energy sensor AMPK |
Q52326182 | Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex |
Q34270994 | Metastasis of benign tumor cells in tuberous sclerosis complex |
Q52145667 | Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor |
Q96607410 | Metformin effectively treats Tsc1 deletion-caused kidney pathology by upregulating AMPK phosphorylation |
Q34325886 | Missense mutations to the TSC1 gene cause tuberous sclerosis complex |
Q47851622 | Modelling Autistic Features in Mice Using Quantitative Genetic Approaches |
Q48023007 | Molecular Basis of Pediatric Brain Tumors |
Q43978101 | Molecular Diagnosis of Genodermatoses |
Q28251056 | Molecular Genetic and Phenotypic Analysis Reveals Differences between TSC1 and TSC2 Associated Familial and Sporadic Tuberous Sclerosis |
Q55981792 | Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumours |
Q42368959 | Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis. |
Q33257900 | Molecular and clinical analyses of 84 patients with tuberous sclerosis complex |
Q30433431 | Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC) |
Q34552842 | Molecular genetic basis of tuberous sclerosis complex: from bench to bedside |
Q89185661 | Molecular genetic diagnostics of tuberous sclerosis complex in Bulgaria: six novel mutations in the TSC1 and TSC2 genes |
Q37183447 | Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities |
Q35469289 | Molecular mechanism of size control in development and human diseases |
Q35089301 | Molecular mechanisms of renal development |
Q36330644 | Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans |
Q35962478 | Molecular pathogenesis of tuber formation in tuberous sclerosis complex |
Q36716971 | Monogenic mouse models of autism spectrum disorders: Common mechanisms and missing links. |
Q35833449 | Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing |
Q35962483 | Mouse models of tuberous sclerosis complex. |
Q28216314 | Multicompartmental distribution of the tuberous sclerosis gene products, hamartin and tuberin |
Q59341135 | Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in -Suppressed Brain |
Q35563126 | Multiple roles of the tuberous sclerosis complex genes |
Q38553435 | Multiplex ligation-depending probe amplification is not suitable for detection of low-grade mosaicism |
Q45185112 | Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex. |
Q77827590 | Mutation of the 9q34 gene TSC1 in sporadic bladder cancer |
Q73111324 | Mutation screening of the entire coding regions of the TSC1 and the TSC2 gene with the protein truncation test (PTT) identifies frequent splicing defects |
Q51005551 | Mutational analyses of the TSC1 and TSC2 genes in cases of tuberous sclerosis complex in Chinese Han children |
Q24535643 | Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs |
Q47101296 | Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece. |
Q30663474 | Mutational analysis of TSC1 and TSC2 genes in gangliogliomas |
Q96576947 | Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex |
Q43862708 | Mutational analysis of TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported |
Q90496167 | Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy |
Q81592302 | Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex |
Q48080915 | Mutational and expression analysis of CDK1, cyclinA2 and cyclinB1 in epilepsy-associated glioneuronal lesions |
Q34088030 | Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis |
Q24681838 | Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation |
Q33681626 | Mutations in the TSC1 gene account for a minority of patients with tuberous sclerosis. |
Q50557999 | Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy |
Q34508924 | Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis |
Q82423814 | Natural history of the Nihon (Bhd gene mutant) rat, a novel model for human Birt-Hogg-Dubé syndrome |
Q37619835 | Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). |
Q26850307 | Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments |
Q28217299 | Neurocutaneous disorders |
Q30680048 | Neurologic manifestations of tuberous sclerosis complex |
Q38525506 | Neurological and neuropsychiatric aspects of tuberous sclerosis complex |
Q51901866 | Neurological aspects of tuberous sclerosis in relation to MRI/MR spectroscopy findings in children with epilepsy |
Q52601345 | Neuronal lysosomes |
Q34432732 | Neuropathology of tuberous sclerosis |
Q35783807 | Neuropsychiatric problems in tuberous sclerosis complex |
Q38983786 | New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex |
Q91880863 | New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids |
Q38137883 | New innovations: therapeutic opportunities for intellectual disabilities |
Q36084916 | New insights into the tumor suppression function of P27(kip1) |
Q74033062 | Non-penetrance in tuberous sclerosis |
Q36162600 | Nonsynonymous Single-Nucleotide Variations on Some Posttranslational Modifications of Human Proteins and the Association with Diseases |
Q28728348 | Non‐canonical functions of the tuberous sclerosis complex‐Rheb signalling axis |
Q41667277 | Novel 23-base-pair duplication mutation in TSC1 exon 15 in an infant presenting with cardiac rhabdomyomas |
Q48603723 | Novel TSC1 and TSC2 mutations in Japanese patients with tuberous sclerosis complex |
Q86884762 | Novel TSC1 mutation associated with variable phenotypes in tuberous sclerosis |
Q74590245 | Novel TSC2 mutation in a patient with pulmonary tuberous sclerosis: lack of loss of heterozygosity in a lung cyst |
Q48459208 | Novel mutation in the TSC2 gene associated with prenatally diagnosed cardiac rhabdomyomas and cerebral tuberous sclerosis |
Q39745229 | Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications |
Q34437857 | Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. |
Q48273239 | Numerous Cortical Tubers and Rhabdomyomas in a Case of Sudden Unexpected Infant Death |
Q42857913 | Nutrients and growth factors in mTORC1 activation |
Q35368205 | Our changing view of the genomic landscape of cancer |
Q52984039 | Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan |
Q36100039 | PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex |
Q36344290 | PEComa: what do we know so far? |
Q24651969 | PEComas: the past, the present and the future |
Q37896509 | PI3 Kinase regulation of neural regeneration and muscle hypertrophy after spinal cord injury |
Q30300538 | PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia |
Q37032524 | PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects |
Q37500523 | PRAS40: target or modulator of mTORC1 signalling and insulin action? |
Q28209980 | Pam and Its Ortholog Highwire Interact with and May Negatively Regulate the TSC1·TSC2 Complex |
Q77752534 | Parallels between tuberous sclerosis complex and neurofibromatosis 1: common threads in the same tapestry |
Q45205869 | Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. |
Q87866079 | Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis |
Q27010355 | Pediatric epileptology |
Q33847771 | Pediatric low-grade gliomas: how modern biology reshapes the clinical field |
Q50310468 | Pervasive Developmental Disorder and Obstetric Complications in Children and Adolescents with Tuberous Sclerosis |
Q34535040 | Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis |
Q33554443 | Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer |
Q28217173 | Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin |
Q38452625 | Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex |
Q42375761 | Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. |
Q36359660 | Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway |
Q37051667 | Possible mechanisms of disease development in tuberous sclerosis |
Q47565388 | Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex |
Q52654761 | Preliminary functional assessment and classification of DEPDC5 variants associated with focal epilepsy |
Q60924052 | Prenatal Neuropathologies in Autism Spectrum Disorder and Intellectual Disability: The Gestation of a Comprehensive Zebrafish Model |
Q52175633 | Prenatal diagnosis of tuberous sclerosis with intracerebral signs at 14 weeks' gestation |
Q48444747 | Prenatal magnetic resonance imaging, ultrasound imaging findings and genetic analysis of concomitant rhabdomyomas and cerebral tuberous sclerosis |
Q45186933 | Prevalence of tuberous sclerosis estimated by capture-recapture analysis. |
Q30361244 | Primary Cilia as a Possible Link between Left-Right Asymmetry and Neurodevelopmental Diseases. |
Q58775480 | Primary angiosarcoma arising in an angiomyolipoma of the kidney: case report and literature review |
Q35203610 | Protein interactome reveals converging molecular pathways among autism disorders |
Q56241321 | Protein truncation test for screening hamartin gene mutations and report of new disease-causing mutations |
Q46582182 | Proton spectroscopic findings in children with epilepsy owing to tuberous sclerosis complex |
Q46950766 | Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex |
Q40303846 | Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis. |
Q24622222 | Pushing the envelope in the mTOR pathway: the second generation of inhibitors |
Q37876523 | Putative roles of cilia in polycystic kidney disease |
Q35575289 | Rab proteins and endocytic trafficking: potential targets for therapeutic intervention |
Q47980226 | Radiobiological Characterization of Tuberous Sclerosis: a Delay in the Nucleo-Shuttling of ATM May Be Responsible for Radiosensitivity. |
Q24194140 | Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex |
Q26471128 | Rapamycin and rapalogs for tuberous sclerosis complex |
Q42871820 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex |
Q34024856 | Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders |
Q86910950 | Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86 |
Q30531079 | Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex |
Q43099344 | Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia |
Q47115233 | Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review |
Q33430534 | Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models |
Q34645240 | Rare and unusual endocrine cancer syndromes with mutated genes |
Q30431817 | Ras and Rap signaling in synaptic plasticity and mental disorders |
Q33755692 | Recent advances in the genetics of epilepsy: insights from human and animal studies |
Q98293148 | Recombinant Tumor Suppressor TSC1 Differentially Interacts with Escherichia coli DnaK and Human HSP70 |
Q35524626 | Reelin' in Genes for Cortical Dysplasia |
Q55463935 | Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. |
Q35546651 | Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex |
Q28262376 | Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent |
Q44533995 | Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products |
Q34488136 | Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K |
Q26995791 | Regulation of mTORC1 by PI3K signaling |
Q27025586 | Regulation of mTORC1 by amino acids |
Q37267573 | Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor |
Q31126940 | Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures |
Q48316314 | Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex |
Q91555958 | Renal disease in tuberous sclerosis complex: pathogenesis and therapy |
Q37400584 | Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? |
Q38556354 | Renal involvement in tuberous sclerosis complex with emphasis on cystic lesions. |
Q40855223 | Renal lesion growth in children with tuberous sclerosis complex |
Q35227615 | Renal manifestations of tuberous sclerosis among children: an Indian experience and review of the literature |
Q54279965 | Renal tumours in a Tsc1+/– mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin |
Q87449061 | Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin |
Q37464956 | Resting and task-modulated high-frequency brain rhythms measured by scalp encephalography in infants with tuberous sclerosis complex. |
Q37962315 | Retinal Manifestations of the Phakomatoses |
Q24648897 | Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis |
Q37260909 | Reversing neurodevelopmental disorders in adults |
Q34810946 | Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. |
Q34136234 | Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis |
Q34472032 | Rheb activation disrupts spine synapse formation through accumulation of syntenin in tuberous sclerosis complex |
Q28207283 | Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins |
Q35077120 | Rheb is essential for murine development |
Q36300188 | Risk factors for the development of autism spectrum disorder in children with tuberous sclerosis complex: protocol for a systematic review |
Q34615463 | Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe |
Q88515019 | Roles for neuronal and glial autophagy in synaptic pruning during development |
Q22008476 | SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome |
Q37634656 | Seizure localization in patients with multiple tubers: presurgical evaluation in tuberous sclerosis |
Q27308143 | Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice |
Q34136115 | Seizures and intellectual outcome: Clinico-radiological study of 30 Egyptian cases of tuberous sclerosis complex |
Q31992449 | Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers |
Q34808699 | Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients |
Q33597406 | Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers |
Q45962222 | Self-reported reproductive health in women with tuberous sclerosis complex. |
Q37350686 | Shank mutant mice as an animal model of autism |
Q24522447 | Signaling by target of rapamycin proteins in cell growth control |
Q28144266 | Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney |
Q47139666 | Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex. |
Q34627013 | Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin |
Q28395313 | Somatic mutation, genomic variation, and neurological disease |
Q38793867 | Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies |
Q77519093 | Some neoplasms and some hamartomatous syndromes: genetic considerations |
Q55361036 | Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis. |
Q27319406 | Stochastic model of Tsc1 lesions in mouse brain |
Q40075039 | Structure of the TBC1D7-TSC1 complex reveals that TBC1D7 stabilizes dimerization of the TSC1 C-terminal coiled coil region |
Q30391512 | Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis |
Q47145272 | Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations |
Q38150748 | Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention |
Q60955528 | Subthreshold micropulse laser photocoagulation therapy in a case of bilateral retinal astrocytic hamartomas with tuberous sclerosis complex: A case report |
Q48232028 | Sudden unexpected death in childhood associated with cardiac rhabdomyoma, involuting adrenal ganglioneuroma, and megalencephaly: another expression of tuberous sclerosis? |
Q74549886 | Summary of ocular genetic disorders and inherited systemic conditions with eye findings |
Q48378903 | Suppressed Expression of Autophagosomal Protein LC3 in Cortical Tubers of Tuberous Sclerosis Complex |
Q36829415 | Suppression of tumor suppressor Tsc2 and DNA repair glycosylase Nth1 during spontaneous liver tumorigenesis in Long-Evans Cinnamon rats |
Q88687508 | Surgery for subependymal giant cell astrocytomas in children with tuberous sclerosis complex |
Q30692065 | Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions |
Q36479094 | Synaptic Plasticity in Mouse Models of Autism Spectrum Disorders |
Q37463670 | T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis |
Q38715345 | TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells |
Q30312086 | TOR signaling |
Q36916367 | TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species |
Q92793948 | TSC1 Gene Therapy AAVerts Neurological Associated Mortality |
Q38434696 | TSC1 R509X Mutation in a Chinese Family with Tuberous Sclerosis Complex |
Q40424038 | TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth |
Q39196241 | TSC1 involvement in bladder cancer: diverse effects and therapeutic implications |
Q33991599 | TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival |
Q43168046 | Targeted deletion of Tsc1 causes fatal cardiomyocyte hyperplasia independently of afterload |
Q35138543 | Targeting Rb inactivation in cancers by synthetic lethality |
Q47562691 | Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development |
Q36313171 | The Akt of translational control |
Q38001221 | The Surgical Approach to Multifocal Renal Cancers: Hereditary Syndromes, Ipsilateral Multifocality, and Bilateral Tumors |
Q24299969 | The TSC1 gene product hamartin interacts with NADE |
Q24306637 | The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton |
Q22254081 | The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho |
Q28507365 | The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins |
Q34420296 | The TSC1-TSC2 complex consists of multiple TSC1 and TSC2 subunits |
Q24645204 | The TSC1-TSC2 complex: a molecular switchboard controlling cell growth |
Q40769463 | The Tuberous Sclerosis 2 Gene Product Can Localize to Nuclei in a Phosphorylation-Dependent Manner |
Q53256800 | The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex |
Q43592528 | The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer |
Q50303440 | The clinical utility of the Social Responsiveness Scale and Social Communication Questionnaire in tuberous sclerosis complex |
Q91955016 | The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas |
Q55067670 | The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. |
Q30365726 | The determinants of head and neck cancer: Unmasking the PI3K pathway mutations |
Q30518266 | The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. |
Q39678422 | The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: a retrospective cohort study in the clinical practice research datalink (CPRD). |
Q39706758 | The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the Clinical Practice Research Datalink |
Q34318188 | The evolution of the TOR pathway and its role in cancer |
Q40399733 | The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity |
Q35746972 | The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms |
Q35210970 | The genetic basis of renal cell carcinoma |
Q51991180 | The genetic basis of tuberous sclerosis |
Q74266215 | The genetics of learning disabilities |
Q33723575 | The genetics of transitional cell carcinoma: progress and potential clinical application |
Q33826893 | The genomic landscape of tuberous sclerosis complex |
Q37831801 | The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling |
Q38108676 | The mTOR Signaling Pathway in Pediatric Neuroblastoma |
Q47575718 | The mTOR inhibitor revolution rolls on. |
Q37197352 | The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells |
Q27010414 | The molecular biology of WHO grade I astrocytomas |
Q36301318 | The molecular genetics of gastroenteropancreatic neuroendocrine tumors |
Q36617717 | The neurobiology of the tuberous sclerosis complex |
Q37139373 | The pathogenesis and imaging of the tuberous sclerosis complex |
Q38724342 | The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. |
Q28590041 | The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis |
Q32033134 | The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis |
Q72997148 | The spectrum of renal cysts in adulthood--discussion of eight cases |
Q39762792 | The transcription factor SP1 regulates centriole function and chromosomal stability through a functional interaction with the mammalian target of rapamycin/raptor complex. |
Q24628011 | The tuberous sclerosis complex |
Q35964423 | The tuberous sclerosis complex genes in tumor development |
Q48354112 | The tuberous sclerosis complex: a comprehensive review |
Q24290817 | The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination |
Q38676485 | The tumor suppressor hamartin enhances Dbl protein transforming activity through interaction with ezrin. |
Q40237430 | Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice |
Q33869969 | Three independent mutations in the TSC2 gene in a family with tuberous sclerosis |
Q47816362 | Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences |
Q33316872 | Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model |
Q34489778 | Toward an etiological classification of developmental disorders of the kidney and upper urinary tract |
Q42822932 | Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain |
Q37737055 | Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality |
Q90428516 | Translation deregulation in human disease |
Q39182861 | Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex. |
Q43136879 | Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa |
Q34731132 | Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. |
Q40711462 | Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling |
Q39654246 | Tsc1 haploinsufficiency is sufficient to increase dendritic patterning and Filamin A levels |
Q28507548 | Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background |
Q36520423 | Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis |
Q53622635 | Tuberin activates the proapoptotic molecule BAD. |
Q44835748 | Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis. |
Q28281015 | Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2 |
Q28211005 | Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis |
Q46845886 | Tuberin--a new molecular target in Alzheimer's disease? |
Q38379999 | Tuberous Sclerosis Complex: An Update for Dermatologists |
Q59330605 | Tuberous Sclerosis Complex: Clinical Spectrum and Epilepsy: A Retrospective Chart Review Study |
Q38414596 | Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management. |
Q47761111 | Tuberous Sclerosis Gene 2 Product Modulates Transcription Mediated by Steroid Hormone Receptor Family Members |
Q83945418 | Tuberous Sclerosis and Epilepsy |
Q64129273 | Tuberous sclerosis |
Q77330384 | Tuberous sclerosis |
Q79990267 | Tuberous sclerosis |
Q82029971 | Tuberous sclerosis |
Q37854881 | Tuberous sclerosis and cardiac rhabdomyomas: a case report and review of the literature |
Q47983543 | Tuberous sclerosis and polycystic kidney disease in a 3-month-old infant |
Q36108778 | Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond |
Q33337266 | Tuberous sclerosis as an underlying basis for infantile spasm |
Q43718788 | Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression |
Q35258306 | Tuberous sclerosis complex and Wolff-Parkinson-White syndrome |
Q36770459 | Tuberous sclerosis complex and epilepsy: recent developments and future challenges |
Q30773684 | Tuberous sclerosis complex and neurofibromatosis type 1: the two most common neurocutaneous diseases |
Q75333522 | Tuberous sclerosis complex and neurofibromatosis type 1: the two most common neurocutaneous diseases |
Q36271047 | Tuberous sclerosis complex and the ketogenic diet |
Q38725858 | Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy |
Q28293292 | Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria |
Q28298922 | Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference |
Q28646935 | Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb |
Q91979647 | Tuberous sclerosis complex presenting as convulsive status epilepticus followed by hypoxic cerebropathy: A case report |
Q33757948 | Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference |
Q37134137 | Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment |
Q38081851 | Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action |
Q38994919 | Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches. |
Q39408346 | Tuberous sclerosis complex: Recent advances in manifestations and therapy. |
Q37678112 | Tuberous sclerosis complex: a brave new world? |
Q36505021 | Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. |
Q35187265 | Tuberous sclerosis complex: everything old is new again |
Q36313189 | Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease |
Q36387783 | Tuberous sclerosis complex: molecular pathogenesis and animal models |
Q36239644 | Tuberous sclerosis complex: neurological, renal and pulmonary manifestations |
Q38297624 | Tuberous sclerosis complex: the past and the future |
Q34276993 | Tuberous sclerosis gene products in proliferation control |
Q48381495 | Tuberous sclerosis-related gene expression in normal and dysplastic brain |
Q34562010 | Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways |
Q35009510 | Tuberous sclerosis: a presentation of less-commonly encountered stigmata |
Q34173640 | Tuberous sclerosis: from tubers to mTOR. |
Q33788736 | Tumor suppressor genes in ophthalmology |
Q90043715 | Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion |
Q35143191 | Tumour suppressors hamartin and tuberin: intracellular signalling |
Q36620770 | Two novel TSC2 mutations in Chinese patients with tuberous sclerosis complex and a literature review of 20 patients reported in China |
Q55365458 | Two target regions of allelic loss on chromosome 9 in urinary-bladder cancer. |
Q33790242 | Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex |
Q42376775 | Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD). |
Q34375358 | Unusual causes of pneumothorax |
Q48717873 | Unusual radiological presentation of tuberous sclerosis complex with leptomeningeal angiomatosis associated with a hypomorphic mutation in the TSC2 gene |
Q36968955 | Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma |
Q35410898 | Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. |
Q48243585 | Value of fetal cerebral MRI in sonographically proven cardiac rhabdomyoma |
Q58705385 | Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis |
Q64095536 | Whole exome sequencing identifies a novel intron heterozygous mutation in TSC2 responsible for tuberous sclerosis complex |
Q30644475 | Wide spectrum of clinical manifestations in children with tuberous sclerosis complex – Follow-up of 20 children |
Q47944047 | dTBC1D7 regulates systemic growth independently of TSC through insulin signaling. |
Q41610591 | gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle |
Q38798392 | mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology |
Q54978861 | mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model. |
Q30539812 | mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. |
Q36919646 | mTOR signalling in human cancer |
Q37350523 | mTOR, a Potential Target to Treat Autism Spectrum Disorder |
Q33292354 | p27Kip1 localization depends on the tumor suppressor protein tuberin |
Search more.